Market closed

Immatics/$IMTX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Immatics

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Ticker

$IMTX

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Tübingen, Germany

Employees

572

Website

www.immatics.com

Immatics Metrics

BasicAdvanced

$713M

-

-$0.63

0.77 -

Price and volume

Market cap

$713M

Beta

0.77

52-week high

$13.77

52-week low

$5.95

Average daily volume

746K

Financial strength

Current ratio

3.978

Quick ratio

3.835

Long term debt to equity

3.45

Total debt to equity

4.189

Interest coverage (TTM)

-77.72%

Management effectiveness

Return on assets (TTM)

-8.28%

Return on equity (TTM)

-17.70%

Valuation

Price to revenue (TTM)

4.889

Price to book

1.61

Price to tangible book (TTM)

1.62

Price to free cash flow (TTM)

-12.686

Growth

Revenue change (TTM)

52.53%

Earnings per share change (TTM)

-43.52%

3-year revenue growth (CAGR)

59.47%

3-year earnings per share growth (CAGR)

-26.01%

What the Analysts think about Immatics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Immatics stock.

Immatics Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Immatics Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Immatics News

AllArticlesVideos

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

GlobeNewsWire·2 months ago

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMTX

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immatics stock?

Immatics (IMTX) has a market cap of $713M as of January 15, 2025.

What is the P/E ratio for Immatics stock?

The price to earnings (P/E) ratio for Immatics (IMTX) stock is 0 as of January 15, 2025.

Does Immatics stock pay dividends?

No, Immatics (IMTX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Immatics dividend payment date?

Immatics (IMTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Immatics?

Immatics (IMTX) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.